Gossamer Bio

GOSS

Market cap $121M

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Gossamer Bio (GOSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 4, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem Hasnain told investors on the Q1 2025 earnings call: "We anticipate announcing top-line results in February 2026" -- guidance that set expectations for a meaningful readout.

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.

LOS ANGELES--(BUSINESS WIRE)---- $GOSS--GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm.

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Gossamer Bio (GOSS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript